Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: One year results from the XIENCE V® USA condition of approval post-market study

Catheterization and Cardiovascular Interventions

Volumn 84, Issue 1, 2014, Pages 7-16

  Hermiller, James B ^a   Rutledge, David R ^b   Mao, Vivian W ^b   Zhao, Weiying ^b   Wang, Jin ^b   Gruberg, Luis ^c   Lombardi, William ^d   Sharma, Samin K ^e   Krucoff, Mitchell W ^f  

^a St Vincent Heart Center of Indiana   (United States)

^b ABBOTT VASCULAR   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d St Joseph Hospital   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

1 year; drug eluting stent; everolimus; small vessel

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; DIABETES MELLITUS; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SEX DIFFERENCE; SMALL VESSEL LESION; STENT THROMBOSIS; SURVIVAL TIME; VASCULAR LESION; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; HEART MUSCLE REVASCULARIZATION; MIDDLE AGED; POSTMARKETING SURVEILLANCE; PROCEDURES; PROSPECTIVE STUDY; PROSTHESIS; RADIOGRAPHY; TREATMENT OUTCOME;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SIROLIMUS; TREATMENT OUTCOME;

EID: 84903546052     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25325     Document Type: Article

References (29)

1. Schunkert H, Harrell L, Palacios IF,. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999; 34: 40-48.
2. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A,. Vessel size and long-term outcome after coronary stent placement. Circulation 1998; 98: 1875-1880.
3. Jabara R, Gradman M, Chen JP, King SB III, Gadesam R, Chronos NA,. Clinical and angiographic features of small vessel stenting in the drug-eluting stent era. Clin Cardiol 2009; 32: E40-E45.
4. Colombo A, Chieffo A,. Drug-eluting stent update 2007: Part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation 2007; 116: 1424-1432.
5. Morice MC,. Stenting for small coronary vessels. J Invasive Cardiol 2003; 15: 377-379.
6. Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hebert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA,. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial (clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 2009; 2: 1190-1198.
7. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ,. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674.
8. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL,. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: Two-year clinical follow-up from the clinical evaluation of the xience V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation 2009; 119: 680-686.
9. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC,. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010; 375: 201-209.
10. Onuma Y, Kukreja N, Piazza N, Eindhoven J, Girasis C, Schenkeveld L, van Domburg R, Serruys PW,. The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol 2009; 54: 269-276.
11. Bartorelli AL, Serruys PW, Miquel-Hebert K, Yu S, Pierson WStone GW,. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv 2010; 76: 60-66.
12. Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW,. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009; 158: 1005-1010.
13. Ito HHJ, Yaqub M, Newman W, Sood P, Wang JC, Cannon L, Maddux JE, Sudhir K, Stone GW,. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: Results from the SPIRIT III and SPIRIT IV clinical trials. J Interv Cardiol 2011; 24: 505-513.
14. Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB,. A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V everolimus eluting coronary stent system condition-of-approval post-market study). JACC Cardiovasc Interv 2011; 4: 1298-1309.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
16. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernandez-Aviles F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N,. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
17. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW,. Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention 2010; 5: 871-874.
18. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ,. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. JAMA 2008; 299: 1903-1913.
19. King SB III, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW,. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol 2008; 51: 172-209.
20. Lasala JM, Cox DA, Dobies D, Baran K, Bachinsky WB, Rogers EW, Breall JA, Lewis DH, Song A, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS,. Drug-eluting stent thrombosis in routine clinical practice: Two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2009; 2: 285-293.
21. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E,. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754.
22. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis JN, Revtyak G, Baim DS,. Usage patterns and 2-year outcomes with the TAXUS express stent: Results of the US ARRIVE 1 registry. Catheter Cardiovasc Interv 2008; 72: 433-445.
23. Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT,. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009; 2: 1227-1235.
24. Mauri L, Orav EJ, O'Malley AJ, Moses JW, Leon MB, Holmes DR Jr, Teirstein PS, Schofer J, Breithardt G, Cutlip DE, Kereiakes DJ, Shi C, Firth BG, Donohoe DJ, Kuntz RE,. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005; 111: 321-327.
25. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Stone GW,. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1193-1200.
26. Moussa I, Moses J, Di Mario C, Albiero R, De Gregorio J, Adamian M, Di Francesco L, Colombo A,. Does the specific intravascular ultrasound criterion used to optimize stent expansion have an impact on the probability of stent restenosis? Am J Cardiol 1999; 83: 1012-1017.
27. Godino C, Furuichi S, Latib A, Morici N, Chieffo A, Romagnoli E, Tamburino C, Barbagallo R, Cera M, Antoniucci D, Goktekin O, Di Mario C, Reimers B, Grube E, Airoldi F, Sangiorgi GM, Colombo A,. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). Am J Cardiol 2008; 102: 1002-1008.
28. Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE,. Zotarolimus-eluting stents in patients with native coronary artery disease: Clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007; 100: 45M-55M.
29. Cannon LA, Simon DI, Kereiakes D, Jones J, Mehran R, Kusano H, Zhang Z, Lombardi W, James Fleischhauer F, Costa MA,. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. Catheter Cardiovasc Interv 2012;80:546-553.